Affordable Access

Publisher Website

Efficacy and duration of action of sustained-release diltiazem in patients with chronic stable effort angina

Authors
Journal
Current Therapeutic Research
0011-393X
Publisher
Elsevier
Publication Date
Volume
54
Issue
6
Identifiers
DOI: 10.1016/s0011-393x(05)80697-6
Disciplines
  • Design
  • Medicine

Abstract

Abstract This double-blind, randomized, placebo-controlled, crossover study was designed to evaluate the effect and duration of sustained-release diltiazem (DTZ-SR) BID in 16 men with stable effort angina. Exercise tests were performed 8 and 12 hours after the administration of DTZ-SR or placebo. Blood samples for diltiazem plasma concentration levels were taken immediately prior to the exercise test at 12 hours. Statistical analysis was performed using an analysis of variance model for a crossover design. Compared with placebo, DTZ-SR significantly prolonged total work from 1982 ± 992 Kjoules/min to 2327 ± 876 Kjoules/min (+17.4%; P < 0.01) at 8 hours and from 1744 ± 691 Kjoules/min to 2414 ± 987 Kjoules/min (+38.4%; P < 0.01) at 12 hours after administration. Work load at ischemic threshold was also significantly prolonged from 1010 ± 384 Kjoules/min to 1249 ± 553 Kjoules/min (+ 23.6%; P < 0.01) at 8 hours and from 963 ± 425 Kjoules/min to 1210 ± 639 Kjoules/min (+26%; P < 0.01) at 12 hours. In conclusion, our data show that this sustained-release diltiazem BID formulation improves the exercise tolerance of patients with chronic angina and this therapeutic effect persists for up to 12 hours after administration.

There are no comments yet on this publication. Be the first to share your thoughts.